These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20066713)

  • 1. Feasibility and tolerability of bevacizumab in children with primary CNS tumors.
    Reismüller B; Azizi AA; Peyrl A; Heinrich M; Gruber-Olipitz M; Luckner D; Rothschild KV; Slavc I
    Pediatr Blood Cancer; 2010 May; 54(5):681-6. PubMed ID: 20066713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors.
    Pansy J; Fritsch P; Sovinz P; Lackner H; Schwinger W; Urban C; Benesch M
    Anticancer Drugs; 2013 Feb; 24(2):198-203. PubMed ID: 23154263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
    Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.
    Couec ML; André N; Thebaud E; Minckes O; Rialland X; Corradini N; Aerts I; Marec Bérard P; Bourdeaut F; Leblond P;
    Pediatr Blood Cancer; 2012 Jul; 59(1):34-8. PubMed ID: 22287258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
    Glade Bender JL; Adamson PC; Reid JM; Xu L; Baruchel S; Shaked Y; Kerbel RS; Cooney-Qualter EM; Stempak D; Chen HX; Nelson MD; Krailo MD; Ingle AM; Blaney SM; Kandel JJ; Yamashiro DJ;
    J Clin Oncol; 2008 Jan; 26(3):399-405. PubMed ID: 18202416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC; Johnston S
    Cancer; 2009 Apr; 115(8):1734-43. PubMed ID: 19197992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in pediatric patients: how safe is it?
    de Pasquale MD; Castellano A; de Sio L; de Laurentis C; Mastronuzzi A; Serra A; Cozza R; Jenkner A; de Ioris MA
    Anticancer Res; 2011 Nov; 31(11):3953-7. PubMed ID: 22110225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
    Patnaik A; LoRusso PM; Messersmith WA; Papadopoulos KP; Gore L; Beeram M; Ramakrishnan V; Kim AH; Beyer JC; Mason Shih L; Darbonne WC; Xin Y; Yu R; Xiang H; Brachmann RK; Weekes CD
    Cancer Chemother Pharmacol; 2014 May; 73(5):951-60. PubMed ID: 24633809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab safety in patients with central nervous system metastases.
    Besse B; Lasserre SF; Compton P; Huang J; Augustus S; Rohr UP
    Clin Cancer Res; 2010 Jan; 16(1):269-78. PubMed ID: 20028762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
    Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
    Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
    Benesch M; Windelberg M; Sauseng W; Witt V; Fleischhack G; Lackner H; Gadner H; Bode U; Urban C
    Ann Oncol; 2008 Apr; 19(4):807-13. PubMed ID: 18056650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.